- Home
- AI vs ARQT Comparison
AI vs ARQT Comparison
Compare AI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AI
- ARQT
- Stock Information
- Founded
- AI 2009
- ARQT 2016
- Country
- AI United States
- ARQT United States
- Employees
- AI N/A
- ARQT N/A
- Industry
- AI Computer Software: Prepackaged Software
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- AI Technology
- ARQT Health Care
- Exchange
- AI Nasdaq
- ARQT Nasdaq
- Market Cap
- AI 2.3B
- ARQT 1.9B
- IPO Year
- AI 2020
- ARQT 2020
- Fundamental
- Price
- AI $15.62
- ARQT $17.15
- Analyst Decision
- AI Hold
- ARQT Strong Buy
- Analyst Count
- AI 15
- ARQT 7
- Target Price
- AI $25.38
- ARQT $19.00
- AVG Volume (30 Days)
- AI 12.8M
- ARQT 1.6M
- Earning Date
- AI 09-03-2025
- ARQT 11-05-2025
- Dividend Yield
- AI N/A
- ARQT N/A
- EPS Growth
- AI N/A
- ARQT N/A
- EPS
- AI N/A
- ARQT N/A
- Revenue
- AI $372,104,000.00
- ARQT $263,464,999.00
- Revenue This Year
- AI $13.06
- ARQT $72.46
- Revenue Next Year
- AI $15.85
- ARQT $32.00
- P/E Ratio
- AI N/A
- ARQT N/A
- Revenue Growth
- AI 14.34
- ARQT 99.50
- 52 Week Low
- AI $14.70
- ARQT $8.03
- 52 Week High
- AI $45.08
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- AI 28.01
- ARQT 65.93
- Support Level
- AI $14.80
- ARQT $15.13
- Resistance Level
- AI $17.54
- ARQT $16.12
- Average True Range (ATR)
- AI 0.71
- ARQT 0.69
- MACD
- AI 0.08
- ARQT 0.06
- Stochastic Oscillator
- AI 22.06
- ARQT 93.61
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.